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Abstract
The 2020 Congress of the International Society of Thrombosis and Haemostasis 
(ISTH) was held virtually July 12-15, 2019, due to the coronavirus disease 2019 pan-
demic. The congress convenes annually to discuss clinical and basic topics in hemo-
stasis and thrombosis. Each year, the program includes State of Art (SOA) lectures 
given by prominent scientists. Presenters are asked to create Illustrated Capsules of 
their talks, which are concise illustrations with minimal explanatory text. Capsules 
cover major themes of the presentation, and these undergo formal peer review for 
inclusion in this article. Owing to the shift to a virtual congress this year, organizers 
reduced the program size. There were 39 SOA lectures virtually presented, and 29 
capsules (9 from talks omitted from the virtual congress) were both submitted and 
successful in peer review, and are included in this article. Topics include the roles of the 
hemostatic system in inflammation, infection, immunity, and cancer, platelet function 
and signaling, platelet function disorders, megakaryocyte biology, hemophilia includ-
ing gene therapy, phenotype tests in hemostasis, von Willebrand factor, anticoagu-
lant factor V, computational driven discovery, endothelium, clinical and basic aspects 
of thrombotic microangiopathies, fibrinolysis and thrombolysis, antithrombotics in 
pediatrics, direct oral anticoagulant management, and thrombosis and hemostasis in 
pregnancy. Capsule authors invite virtual congress attendees to refer to these cap-
sules during the live presentations and participate on Twitter in discussion. Research 
and Practice in Haemostasis and Thrombosis will release 2 tweets from @RPTHJournal 
during each presentation, using #IllustratedReview, #CoagCapsule and #ISTH2020. 
Readers are also welcome to utilize capsules for teaching and ongoing education.
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Fibrin microfilms protect clots from microbes
Robert Ariëns PhD
When thrombin cleaves fibrinogen, the resulting fibrin was known to spontaneously polymerize into protofibrils that aggregate and branch to 
form fibrin fibers. The fibrin fibers provide the structural and elastic backbone to the blood clot. Our recent study has shown that fibrin can 
also produce Langmuir-Blodgett films at phase boundaries (eg the liquid/air interface).1 These fibrin films help to trap host cells into the clot, 
and prevent microbial infection from entering the clot to infect the host. Films have also been observed on intracoronary thrombi obtained 
by thrombectomy from patients with myocardial infarction,2 and from clots obtained by stent retriever from patients with ischemic stroke.3 
Films or shell-like structures in intravascular thrombi have been reported to slow down thrombolysis,3 but their origin and full functional role(s) 
require further investigation.
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Managing DOACs in emergencies
Cecilia Becattini MD, PhD
Clinicians should tailor treatment of patients with emergencies occurring while on treatment with direct oral anticoagulants (DOACs) based on the 
severity of major bleeding and the need for emergency access to the operative room.4,5 Interruption of DOACs and general supportive measures 
should be considered while trying to confirm that anticoagulant treatment has a role in bleeding and/or in deciding the timing of surgery. Time and 
dose of last intake, renal function, and the measurement of plasma levels of DOAC, if available, should be considered.6 If measurement of plasma 
levels of DOAC is not feasible, standard coagulation tests can be useful to assess DOAC-related anticoagulation.
No evidence on the effect of idarucizumab and andexanet in survival has been reported so far. Effective hemostasis is assessed by methods 
developed for assessment of prothrombin complex concentrates in warfarin reversal for andexanet and by diluted thrombin time or ecarin 
clotting time for idarucizumab.4,5
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Platelet cytoskeleton and its disorders
Markus Bender PhD
For references, see Hartwig7 and Schurr et al.8
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Small GTPases in megakaryocyte and platelet biology
Wolfgang Bergmeier PhD
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Anticoagulant factor V
Elisabetta Castoldi PhD
It is common knowledge that activated factor V (FVa) expresses procoagulant activity as an essential cofactor of factor Xa (FXa) in prothrombin 
(PT) activation. What is less appreciated is that as long as it is not (fully) activated, FV contributes to the anticoagulant cause by (i) maintaining 
tissue factor pathway inhibitor-α (TFPIα) in the circulation; (ii) enhancing the inhibition of FXa by TFPIα and protein S (PS); and (iii) stimulating the 
inactivation of factor VIIIa (FVIIIa) by activated protein C (APC) and PS. The first 2 anticoagulant functions are most pronounced in FV-short, a FV 
splicing variant present in plasma at sub-nM concentrations. The third anticoagulant function requires cleavage of single-chain FV by APC. The 
physiopathological relevance of these anticoagulant mechanisms is underscored by genetic defects that enhance (FV East-Texas) or impair (FV 
Leiden) the anticoagulant properties of FV, thereby increasing the risk of bleeding or venous thrombosis.9
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Laboratory diagnosis of antiphospholipid syndrome
Katrien M. J. Devreese MD, PhD
The diagnosis of antiphospholipid syndrome (APS) relies on detection of antiphospholipid antibodies (APAs). APAs are a heterogeneous 
group of antibodies, but only lupus anticoagulant (LAC), anticardiolipin (aCL) and anti-β2-glycoprotein I antibodies (aβ2GPI) IgG or IgM are 
included in the laboratory criteria. At least 1 criterion has to be persistently positive.10 LAC measurement remains a complex procedure with 
a 3-step procedure, including screening, mixing, and confirmatory tests in 2 test systems. Solid-phase assays for aCL and aβ2GPI show inter-
assay differences. These methodological issues make the laboratory diagnosis of APS challenging, although progress has been made on the 
standardization and interpretation as reflected in published guidelines on LAC testing and solid-phase assays for aCL and aβ2GPI.10-12 Other 
APAs, not included in the current criteria, such as antibodies against the domain I of β2GPI and antiphosphatidylserine-prothrombin antibodies 
may be useful in risk stratification but have no added value for diagnosis of APS.
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Myeloproliferative neoplasms in pregnancy: Implications for 
mother and child
Martin H. Ellis MD
Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (termed myeloproliferative neoplasms [MPNs]) are clonal 
diseases that may result in fatal end-stage bone marrow fibrosis or acute leukemia. During the long natural history of these diseases, particu-
larly PV and ET, thrombosis is an important complication.
The median age at diagnosis of the MPNs is >60 years; however, 20% are <40 years old when diagnosed. Thus, there is a need to provide ap-
propriate treatment to pregnant patients with MPNs.
Maternal (venous or arterial thrombosis or hemorrhage), or placenta-related (fetal loss or preeclampsia/eclampsia) complications may occur 
during pregnancy. The incidence and risk factors for complications are poorly defined.
Treatment has been observational data and expert opinion based. Recently a meta-analysis of randomized clinical trials has provided a basis 
for decision making; however, more data from prospective or registry studies is required to inform appropriate treatment for these patients.13
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Clinical heterogeneity in factor XI deficiency
David Gailani MD
Factor XI (FXI) is the precursor of FXIa, a protease that contributes to thrombin generation by activating factor IX.14 While critical to clotting 
in the activated partial thromboplastin time assay, FXI makes modest contributions to hemostasis.15 Furthermore, bleeding in FXI-deficient 
patients correlates poorly with plasma FXI levels.15 Indeed, completely deficient patients may not experience abnormal bleeding. Thrombin 
generation is controlled by a group of vitamin K–dependent proteases and their cofactors.16 The process is initiated at an injury site by a com-
plex of factor VIIa and tissue factor (TF). In this scheme, FXI serves an ancillary role, supplementing factor IXa generated by VIIa/TF.16 Given 
this, it seems likely that a number of processes that alter thrombin generation, platelet activity, or fibrinolysis would affect the requirement for 
FXIa activity in different individuals, and in different tissues. Contributors to variable bleeding in FXI-deficiency may well be similar to those 
that influence bleeding in people with hemophilia.
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Proteomics of the hemostatic system
Vera Ignjatovic PhD
Proteomics, as the study of proteins as the functional elements and main drivers of phenotype, is extremely important when it comes to under-
standing developmental biology. In addition, proteomics, via biomarker discovery, allows for early detection of disease. However, proteomics 
has, at least until very recently, been underutilized in the setting of thrombosis and hemostasis. We have recently used a proteomics approach 
to characterise age-specific changes in the hemostatic plasma proteins. This figure outlines age-specific changes in expression of 27 proteins 
that are associated with coagulation and/or serve as markers of platelet activation or endothelial involvement. Holistic proteomic analysis in 
the background of dynamic, age-specific nature of hemostasis yields new insights and sets a new standard for using proteomics in thrombosis 
and hemostasis.17
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von Willebrand factor in angiogenesis and angiodysplasia in 
patients
Paula D. James MD
Angiodysplasia is increased in patients with congenital von Willebrand disease (VWD) and acquired von Willebrand syndrome (AVWS). Both 
groups of patients experience intractable gastrointestinal bleeding that is often very difficult to treat. Previous studies have shown that en-
dothelial von Willebrand factor (VWF) is a negative regulator of angiogenesis.18 Patient derived endothelial colony-forming cells from both 
patients with type 3 VWD and patients with aortic stenosis (AVWS) display abnormal angiogenesis in vitro.19,20 In vivo studies in VWF knock-
out mice show increased vessel growth in the ears and increased tubule formation in Matrigel plugs at 7 days when compared with wild type.
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Vascular endothelial cell dysregulation during sepsis
Steve Kerrigan PhD
Sepsis is of significant global concern with 49 million new cases of sepsis worldwide per year and 11 million deaths.21 Sepsis is defined as a 
life-threatening organ dysfunction caused by a dysregulated host response to infection. The vascular endothelium is a major target of sepsis-
induced events.22 Pathogen binding to the vascular endothelium is seen as a pivotal step in driving the dysregulated response to the infection. 
For example, endothelial dysregulation results in dysfunction of anticoagulation and places the system into a hypercoagulant state. A break-
down of the endothelial barrier results in dissemination of bacteria to distant sites and fluid leakage into the extravascular space leading to 
life-threatening edema in the lungs, kidney, and brain that can progress to multiorgan failure.22 The vascular endothelium is therefore a major 
target of novel therapies to disrupt pathogen attachment in an attempt to slow or stop progression of sepsis to a life-threatening situation.23
694  |     ILLUSTRATED REVIEW
Clinical versus genetic approaches to the diagnosis of platelet 
function disorders
Michele P. Lambert MD, MSTR
• Requires the coordination of laboratory evaluation with genetic testing:
• Improve patient outcomes
• Increase knowledge
• Guidelines are needed that reflect this recommendation:
• Make this the standard of care
• Provide access to testing
• Require genetic counseling
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Obstetric antiphospholipid syndrome
Lai Heng Lee MBBS, M Med, FAMS (Int Med), FRCP (UK)
For references see Miyakis et al,24 Alijotis-Reig et al,25 and Ruffatti et al.26
Diagnosc Criteria for Anphospholipid Syndrome (APS)
At least one clinical and one laboratory criteria are present
Clinical Criteria 
Thromboc events  
Obstetric Complicaons
Recurrent early miscarriages
Unexplained fetal death
Preterm delivery from pre-eclampsia or placenta insufficiency
Laboratory Criteria
Posive an-phospholipid anbodies
Ancardiolipin, 
An-beta2-GP1
Lupus Ancoagulant
Concerns in Diagnosc Criteria of Obstetric APS
Clinical features non specific
Beer defined updated diagnosc criteria needed
Pathogenesis in Obstetric APS 
Incompletely understood
Immune mediated acvaon of inflammatory cascades
and complement acvaon
Thrombosis, infarcon and necrosis of placenta
Treatment Strategies to minimise the risks of adverse maternal and foetal outcomes
Strafy Risk profiles
High Quality Clinical trial data lacking
Standard treatment - Low molecular weight heparin, low dose aspirin 
High risks and refractory cases –  steroids, hydroxychloroquine, pravastan, IVIG, aphaeresis
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Drug-associated thrombotic microangiopathies: Emerging 
toxicities of novel drugs
Marcel Levi MD, PhD, FRCP
For references see Pisoni et al,27 Kreuter and Winters,28 and Levi and Sivapalaratnam.29
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Platelet-derived microparticles in autoimmune diseases
Norma Maugeri PhD
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TAFI pathway in hemophilia
Joost Meijers PhD
For references, see Wyseure et al30,31 and Semeraro et al.32
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Cell therapy using endothelial progenitor cells
Juan Melero-Martin PhD
Human induced pluripotent stem cell (iPSC)–derived endothelial cells (iECs) have become a valuable tool in regenerative medicine. Our group 
has recently developed an application for the treatment of hemophilia A that entails bioengineering patient-specific microvascular grafts for 
the delivery of full-length factor VIII into the bloodstream.33 To this end, we first generated patient-specific iPSCs from urine epithelial cells 
and genetically modified them using a nonviral piggyBac DNA transposon system to insert multiple copies of the full-length F8 gene. We 
subsequently differentiated the modified F8-iPSCs into competent F8-iECs and demonstrated that the cells were capable of producing high 
levels of FVIII. Importantly, following subcutaneous implantation into immunodeficient hemophilic (SCID-f8ko) mice, we demonstrated that 
the F8-iECs were able to self-assemble into vascular networks, and that the newly formed microvessels had the capacity to deliver functional 
FVIII directly into the bloodstream of the mice, effectively correcting the clotting deficiency.
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When and how to use antiplatelet agents in children
Alan D. Michelson MD
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Immunogenicity of adeno-associated vectors
Federico Mingozzi PhD
The adeno-associated virus (AAV) vector gene-transfer platform has an attractive safety and long-term efficacy profile demonstrated in a number 
of trials for hemophilia A and B. Because humans are naturally exposed to wild-type AAV, they develop both antibody and T-cell immunity to the 
virus. AAV vectors, like their wild-type counterpart, interact with the host immune system at multiple levels, starting early after vector administra-
tion with the induction of innate immune responses. Early activation of immunity is followed by adaptive immune responses, which result in long-
term development of neutralizing antibodies and activation of capsid T-cell responses directed against the vector capsid. When not adequately 
managed, immune responses to AAV vectors can be associated with short-lived or absent expression of the therapeutic transgene.34
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Computationally driven discovery in coagulation dynamics
Keith Neeves PhD
For references, see Link et al35,36 and Biorender.com.37
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GPIbα-driving force for liver thrombopoietin generation
Heyu Ni MD, PhD
Platelet GPIbα plays important roles in thrombosis and hemostasis, but its role in thrombopoietin (TPO) generation was not previously explored. 
TPO is predominantly produced by the liver, and its circulating levels have been thought to be maintained through its clearance by platelets and 
megakaryocytes via surface c-Mpl internalization. Unexpectedly, we found TPO levels have a 2- to 3-fold decrease in both GPIbα deficient mice 
and human patients with Bernard-Soulier syndrome (BSS). Transfusion of platelets from wild-type but not GPIbα-/- or interleukin-4/GPIbα trans-
genic mice increased the TPO level in GPIbα-/- mice via de novo TPO synthesis in the liver. In vitro cell culture assays further demonstrate GPIbα-
hepatocyte interaction is the driving force for TPO generation, which can be inhibited by antibodies blocking the N-terminus of GPIbα. These 
findings may have important implications in diseases related to GPIbα such as BSS and immune-mediated thrombocytopenia. We are studying the 
molecular and cellular mechanisms behind this “driving force.”38-40
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The role of platelets in tumor metastasis
Anna-Karin Olsson MD, PhD
Platelets activated in the tumor microenvironment secrete platelet-derived growth factor subunit B (PDGFB) that contributes to the vascular 
remodeling process. (A) In healthy tissue, platelets stay in the circulation in a nonactivated state, since they do not come in contact with sub-
endothelial components such as tissue factor (TF) and collagen. (B) In contrast, the discontinuous endothelium in tumors expose platelets to 
subendothelial spaces, leading to their activation and degranulation in close proximity to the vasculature. Platelet-derived PDGFB will, in the 
same was as endothelial-derived PDGFB, be retained close to the vasculature due to the heparan sulfate–binding retention-motif and contrib-
ute to the pericyte-recruiting gradient of PDGFB.
pericyte precursor platelet
activated platelet
platelet-derived PDGFB
endothelial cell
collagen
TF
Healthy blood vessel Tumor blood vessel (A) (B)
endothelial-derived PDGFBpericyte
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Treatment of complement-mediated thrombotic 
microangiopathies
Zoltán Prohászka MD
Thrombotic microangiopathies (TMAs) are heterogeneous diseases with common pathogenic features including endothelial activation and 
damage, aggregation and consumption of platelets, and hemolysis consequent to mechanical injury to erythrocytes (1). TMAs are rapidly pro-
gressing diseases when untreated; therefore, the decision to start the initial, lifesaving treatment should be done quickly, based on clinical and 
laboratory signs and careful evaluation of the presenting features (2). However, since various targeted therapies are now available to target the 
molecular etiologic factors or key pathogenic mediators of TMAs, it is of utmost importance to rapidly evaluate the molecular etiology behind 
TMAs and make discrimination between complement-mediated disease forms including, for example, atypical hemolytic uremic syndrome 
(aHUS) and other forms of TMAs (2 and 3). First-line therapy of aHUS in pediatric patients is based on complement inhibitory drugs, and for 
adults, early change from plasmapheresis to complement inhibitory therapy is indicated in case of plasma resistance or plasma dependence (3). 
There are attempts to identify factors (including rare or common variants of complement genes) that may help facilitate decisions on the length 
of complement inhibitory therapy (4). For those necessitating kidney transplantation due to complement-mediated TMA, peritransplantation 
management, including the application of complement inhibitory drugs, should be based on careful genetic evaluation of complement factors 
and regulators (5).
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Fibrinolytic factors in cancer progression
Marie Ranson PhD
For references, see Harris et al,41 Stutchbury et al,42 and Buckley et al.43
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DOACs for unusual site venous thromboembolism
Nicoletta Riva MD
Treatment of unusual site venous thromboembolism (VTE) can be challenging, due to the relative rarity of these thromboses and the pau-
city of strong evidence in the literature. Patients with unusual VTE were not included in the large phase 3 trials assessing the direct oral 
anticoagulants (DOACs), but several case series, retrospective and prospective studies, and two small randomized controlled trials44,45 were 
recently published. Currently available results suggest that the safety and effectiveness of the DOACs in upper-extremity deep vein throm-
bosis (UEDVT)46 is comparable to lower-limb deep vein thrombosis and pulmonary embolism. Studies in splanchnic vein thrombosis (SVT) and 
cerebral vein thrombosis (CVT) showed promising results, although hampered by low number of patients, variable study design and outcome 
definitions, and heterogeneity of results, which resulted in a wide range of the major clinical outcomes. A number of ongoing studies will 
provide further evidence on unusual VTE.
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Tyrosine kinases-phosphatases and platelet activation
Yotis Senis MSc, PhD
Platelet activation is a tightly controlled process, allowing platelets to respond rapidly to vascular injury, while preventing pathological throm-
bosis. Reversible tyrosine phosphorylation is a primary mode of signal transduction catalyzed by the opposing activities of protein-tyrosine 
kinases (PTKs) and phosphatases (PTPs), mediating binding of Src homology 2 (SH2) domain-containing proteins to phosphotyrosine residues 
(p-Tyr), and altering the catalytic activity of enzymes. Src family kinases (SFKs) are essential for initiating and propagating signals from a 
diverse repertoire of platelet receptors, including GPVI-FcR γ-chain, GPIb-IX-V, P2Y12, αIIbβ3 and G6b-B.
47 The structurally distinct PTKs 
spleen tyrosine kinase (Syk) and Bruton’s tyrosine kinase (Btk) play vital roles in amplifying activation signals, whereas C-terminal Src kinase 
(Csk) and Csk homologous kinase (Chk) inhibit SFK activity.48 PTPs are equally important regulators of platelet activation, notably, the PTP 
receptor-type J (PTPRJ, also referred to CD148), which both activates and attenuates SFK activity48; and the nontransmembrane SH2 domain-
containing PTPs 1 and 2 (Shp1, Shp2), critical for transmitting inhibitory signals from G6b-B.49 Understanding the molecular interplay between 
PTKs and PTPs has important scientific and clinical implications, as tyrosine kinase inhibitors are increasingly used clinically, and tyrosine 
phosphatase inhibitors come into use.
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DOACs in children: Current evidence and future perspectives
Cornelia H. van Ommen MD, PhD
The first phase 3 direct oral anticoagulant (DOAC) study for the treatment of pediatric venous thromboembolism (VTE) showed similar safety and 
efficacy in the rivaroxaban and standard of care groups.50 Consequently, DOACs will probably become the anticoagulants of choice in children. 
However, certain limitations should be considered. In the rivaroxaban trial, only 37 children <2 years were included. Neonates had to have a ges-
tational age of at least 37 weeks and oral feeding for 10 days; most neonates with VTE will not meet this requirement. Heavy menstrual bleeding, 
frequently seen in female DOAC users, may be a problem for adolescents with estrogen-associated VTE. Finally, adherence issues with DOACs 
might be a reason to switch back to “old-fashioned” anticoagulants to increase contact between patients and caregivers. Consequently, postau-
thorization studies are needed, which require international registries such as the Throm-PED registry.51 At present, antithrombotic treatment in 
children requires a personalized approach.
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PAI-1 and the multimorbidity of aging
Douglas E. Vaughan MD
Plasminogen activator inhibitor-1 (PAI-1) is a functional mediator of cellular senescence. Experimental evidence has uncovered direct mecha-
nistic links between PAI-1 and aging-like pathology. Conversely, PAI-1 deficiency provides protection against aging-related pathologies in 
experimental models. Furthermore, in healthy human populations, plasma PAI-1 predicts the development of vascular stiffness, coronary 
disease, diabetes, and hepatic steatosis. We have shown that PAI-1 deficiency protects against emphysema and arteriosclerosis and quadru-
ples life span in a mouse model that resembles accelerated human aging. In a remarkable “natural” randomized study in humans, heterozygous 
carriers of a null variant in the gene that codes for PAI-1 (SERPINE1) have longer telomeres, lower fasting insulin levels, protection from dia-
betes, preserved vascular flexibility, and a longer life span than their unaffected kindred. Based on experimental evidence in cells and mice, 
epidemiologic studies, and findings in a unique human population, PAI-1 is a validated target for the prevention of numerous aging-related 
morbidities and perhaps even aging itself.52-54
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Visualizing thrombosis to improve thrombolysis
John Weisel PhD
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